Shire’s once-daily Intuniv has been approved in Europe for use in children and adolescents with attention-deficit hyperactivity disorder, offering another non-stimulant treatment option.

The regulatory nod means that the extended release version of Intuniv (guanfacine) can now be used to treat ADHD in patients aged six to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

The drug is the first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the European Union, and becomes only the second non-stimulant on the market for this patient group.

“The importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents,” stressed Perry Sternberg from Shire’s Neuroscience Business Unit.